nect Biopharma (US:CNTB) Jin Rong Jie·2025-08-22 13:52Core Viewpoint - Conformative Biopharma (CNTB) has experienced a significant decline in revenue and net profit, indicating potential challenges in its financial performance and market position [1] Financial Performance - As of June 30, 2025, Conformative Biopharma reported total revenue of $48,000, representing a year-over-year decrease of 99.8% [1] - The company recorded a net loss attributable to shareholders of $23.171 million, which is a staggering year-over-year decline of 476.52% [1] Market Activity - On August 22, CNTB opened with a 2.31% increase, trading at $1.77 per share, with a total trading volume of $352.0 [1] - The company's total market capitalization stands at approximately $98.6273 million [1] Company Overview - Conformative Biopharma is a biopharmaceutical company in the clinical stage, focusing on developing innovative therapies through its proprietary T-cell functional modulation platform to improve the quality of life for patients with inflammatory immune diseases [1]